- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
SABS
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
SAB Biotherapeutics Inc · Healthcare · Biotechnology
Latest close
3.57 USD
1.7%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -6.0% below the Trend Line and sits at 52.1% of its 52-week range. The latest completed week returned 1.7%, after a -8.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 48/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.
Setup score
25
out of 100
Latest Close
3.57 USD
31 Jul 2026
1W Return
1.7%
latest completed week
4W Return
-8.9%
short-term follow-through
12W Return
-13.1%
quarterly tape
Trend Breadth
73.1%
38 of 52 weeks active
Volume Ratio
0.4x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.7%
Latest completed week; four-week move -8.9%.
Indicator stack
40/40
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 41.38%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
48/100 conviction; expected move 25.6%.
News sentiment
55/100
47 relevant articles in the latest sentiment read.
Event risk
4d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -6.0% below the Trend Line and sits at 52.1% of its 52-week range. The latest completed week returned 1.7%, after a -8.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3312-week average 0.32
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.33Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -8.9% over four weeks, -13.1% over 12 weeks, and 60.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year38
Trend breadth73.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.49Latest activity-pressure read.
Pressure change-15.4%Four-week change in activity pressure.
Leadership-4.37Latest relative-leadership reading.
RS change-281.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 70%
Model confidence 67%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength40/100Blend of value, momentum, and quality. Underlying universe rank 61; rank 1 is best.
Value45/100Relative valuation strength. Underlying universe rank 56; rank 1 is best.
Quality44/100Profitability and accounting quality. Underlying universe rank 57; rank 1 is best.
Momentum45/100Medium-term price momentum. Underlying universe rank 56; rank 1 is best.
Growth45/100Revenue and earnings growth. Underlying universe rank 56; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- 86.4x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -19.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -0.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -62.9% Net share repurchases relative to market value.
- Shareholder yield
- -62.9% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -4.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
SABS shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 0.13, expected move of 25.6%, and Sharemaestro trend signal inactive.
Conviction48/100
Expected move25.6%
Put/call volume0.13
Insider activity0 / 1
0 acquisitions and 1 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment55/100
Weighted news tone is neutral across 47 relevant articles.
15 positive · 30 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move25.6%Nearest-chain priced movement where available.
52-week drawdown-30.7%Distance below the 52-week high.
13-week volatility9.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher10 of 2616 weeks finished lower.
Best week+20.1%Week of 19 Jun.
Worst week-10.0%Week of 15 May.
Latest week+1.7%Week of 31 Jul.
Shape of recent returns
Strong gains5
Modest gains5
Flat weeks0
Modest losses5
Sharp losses11
Recent vol9.1%13-week weekly-return volatility.
Base vol8.6%52-week weekly-return volatility.
Up/down split25/26Count of positive and negative weeks in the 52-week window.
Average skew8.2% / -5.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape28/100
Trend, activity pressure, participation, and risk combine to a 28/100 tape read.
Indicator analysis22/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 5/12.
Activity pressure 0.33; No reversal markers Next-Week ExpectancyNegative 41.38%Next-week expectancy is negative with a 41.38% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors42/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 97; Small Cap Core rank 57 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options34/100SABS shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 0.13, expected move of 25.6%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 25.6% Sentiment55/100Weighted news tone is neutral across 47 relevant articles.
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders0 / 10 acquisitions and 1 disposals in the latest 180-day insider tape.
Earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 3.57 USD | 1.7% | 3.80 USD | 3.86 USD | -0.49 | -4.37 | 1.8M | Off |
| 24 Jul 2026 | 3.51 USD | -0.8% | 3.81 USD | 3.89 USD | -0.45 | -5.07 | 3.3M | Off |
| 17 Jul 2026 | 3.54 USD | -7.3% | 3.81 USD | 3.92 USD | -0.31 | -5.58 | 2.1M | Off |
| 10 Jul 2026 | 3.82 USD | -2.6% | 3.83 USD | 3.95 USD | -0.15 | -2.18 | 3.3M | Off |
| 3 Jul 2026 | 3.92 USD | 3.2% | 3.83 USD | 3.99 USD | -0.42 | 2.40 | 1.6M | Off |
| 26 Jun 2026 | 3.80 USD | -5.0% | 3.83 USD | 4.01 USD | -0.68 | 0.99 | 7.7M | Off |
| 19 Jun 2026 | 4.00 USD | 20.1% | 3.84 USD | 4.04 USD | -0.89 | 2.36 | 11.5M | Off |
| 12 Jun 2026 | 3.33 USD | -1.5% | 3.83 USD | 4.07 USD | -1.02 | -11.86 | 1.5M | Off |
| 5 Jun 2026 | 3.38 USD | -6.1% | 3.83 USD | 4.10 USD | -0.87 | -8.02 | 2.0M | Off |
| 29 May 2026 | 3.60 USD | -7.7% | 3.83 USD | 4.14 USD | -0.57 | -5.97 | 1.1M | Off |
| 22 May 2026 | 3.90 USD | 5.4% | 3.81 USD | 4.18 USD | -0.65 | 5.26 | 2.5M | Off |
| 15 May 2026 | 3.70 USD | -10.0% | 3.79 USD | 4.21 USD | -0.84 | 1.79 | 5.9M | Off |
| 8 May 2026 | 4.11 USD | 18.4% | 3.75 USD | 4.24 USD | -0.83 | 13.41 | 11.1M | On |
| 1 May 2026 | 3.47 USD | -1.4% | 3.68 USD | 4.27 USD | -1.04 | 1.82 | 2.3M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.